Molecular Target for Screening: G-Protein-Coupled Receptors, ActiTarg-G
Filed under: Chemistry News, Compound Libraries, Compounds for HTS, New Products
Newark, DE. August, 2010 – Press Release – TimTec, LLC. – Molecular Target for Screening: G-Protein-Coupled Receptors, ActiTarg-G
G-Protein-Coupled Receptors are the largest gene families in the human genome and, rightfully so, have become the leading molecular target in 2008. In 2009 SBS April meeting in Lille, France, followed-up with screening trends report stating that “GPCRs are expected to replace protein kinases as the most common molecular target used by HTS laboratories.”
GPCRs are the largest family of cell surface receptors being integral to the number of cellular and physiological functions, including light sensing, smell, appetite control, insulin secretion, and blood pressure modulation. These receptors generally have a seven-membrane spanning alpha-helical topography, and while these receptors are similar in overall structure and function, they differ in key amino acid residues. The potential for this super family of receptors to reveal small molecule modulators of a significant biological function has been responsible for the focus of intense drug discovery efforts.
TimTec GPCR Ligands library is called ActiTarg-G. It currently counts 2,300 molecules available in various formatting options, and can be delivered in vials or in 96 or 384-well plates. ActiTarg-G is the set of diverse molecules that contain chemical lattices present in compounds reported in the technical or patent literature to possess GPCR-ligand properties.
Contact Information to schedule free consultation:
TimTec LLC
Harmony Business Park A-301
Newark DE 19711
Tel 302 292 8500
Fax 302 292 8520
Web: http://www.timtec.net/news/timtec-news/actitarg-g-gpcr-ligandshtml.html
About TimTec
TimTec LLC is a privately held company located in Newark Delaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds and collections, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.
FEP Multi-Channel Distillation Column Packing
Solvent recycling saves money and is good for the environment. Using our PFE column packing, solvents can be efficiently recovered and reused, reducing environmental burden and spent solvent disposal costs. With the proper column height, solvents can be restored to their original purity or better.
The packing’s unique geometric shape was developed in our chemical R&D laboratories for the purification of deuterated solvents and solvent recovery. Liquid does not pool irregardless of packing orientation. The surface is completely inert to polar and non-polar solvents, acids and bases, thereby eliminating any possible metal, organo-metalic, or monomer contamination as when using other packing materials. Due to the inert nature of PFE, cleaning and drying the packing for later use is easy and straight forward.
As an example of its distillation efficiency, we were able to produce 99.9% atom D2O from water using regular types of distillation columns and receivers. We have also distilled organic solvents to 99.99% purity and have recycled these for our own use. If you are interested in solvent recovery, whether for HPLC, HPLC-NMR, wet chemistry or other use, Norell’s PFE column packing is the leading product of choice.
http://www.nmrtubes.com/
Neuronetrix’ COGNISION™ System
Alzheimer’s disease is a chronic neurodegenerative disease of the brain which afflicts roughly 5 million individuals in the United States. Approximately 10% of those over 65 and 50% of those over 85 will die as a result of Alzheimer’s disease.
Even with several therapies available to treat Alzheimer’s disease, there still is a significant gap between the onset of the disease and point at which treatment actually begins. This treatment gap is directly tied to the challenges in diagnosing the disease early, before the significant loss of memory, cognition, and activities of daily living. Patients, doctors, caregivers, and the pharmaceutical industry, are looking for and demanding a solution to this problem.
Neuronetrix’ COGNISION™ System will, for the first time, directly detect the abnormal cognitive effects of Alzheimer’s disease! This will facilitate an earlier and more accurate diagnosis than is currently available. Physicians will use the COGNISION™ test to determine which patients would benefit from the available drug treatments. The system can also be used to monitor the efficacy of the prescribed therapy.
With the aging of America and the proliferation of new Alzheimer’s therapies, the market for Alzheimer’s screening could approach several billion dollars per year in the United States alone.
Following the validation of the COGNISION™ System for Alzheimer’s disease, Neuronetrix will expand into other neurodiagnostic markets such as ADHD, dyslexia, and depression.
http://www.neuronetrix.com/